Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells

Experimental and Molecular Medicine

Volumn 37, Issue 4, 2005, Pages 353-364

  Joung, Youn Hee ^a   Lim, Eun Joung ^a   Lee, Moon Young ^a   Park, Jong Hwan ^b   Ye, Sang Kyu ^c   Park, Eui U ^a   Kim, Sang Yoon ^a   Zhang, Zheng ^d   Lee, Kwang Jeon ^e   Park, Dong Ki ^e   Park, Taekyu ^a   Moon, Won Kook ^f   Yang, Young Mok ^a  

^a Konkuk University   (South Korea)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c Seoul National University College of Medicine   (South Korea)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e Konkuk University   (South Korea)

^f NONE   (South Korea)

Author keywords

Breast neoplasms; Cell hypoxia; Cyclin D1; Janus kinase 2; Stat5 protein; Trans activation

Indexed keywords

CYCLIN D1; DEFEROXAMINE; JANUS KINASE 2; SERINE; STAT5A PROTEIN; STAT5B PROTEIN; TYROSINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL HYPOXIA; CELL LINE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 24944510719     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2005.45     Document Type: Article

References (42)

1. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-97
2. Bando H, Toi M, Kitada K, Koike M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed Pharmacother 2003;57:333-40
3. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-61
4. Bienvenu F, Gascan H, Coqueret O. Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism. J Biol Chem 2001;276:16840-7
5. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88
6. Brahimi-Horm C, Berra E, Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 2001;11:832-6
7. Brockman JL, Schroeder MD, Schuler LA. PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 2002;16:774-84
8. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell 1999;98:295-303
9. de Groot RP, Radijmakers JA, Lammers JW, Koenderman L. STAT5-Dependent Cyclin D1 and Bcl-xL Expression in Bcr-Abl-Transformed Cells. Mol Cell Biol Res Commun 2000;3:299-305
10. Frasor J, Barkai U, Zhong L, Fazleabas AT, Gibori G. PRL-induced ERα gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase. Mol Endocrinol 2001;15:1941-52
11. Fukuchi K, Tomoyasu S, Tsuruoka N, Gomi K. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett 1994; 350:139-42
12. Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 1999;10:131-57
13. Harris AL. Hypoxia a key regulatory factor in tumor growth. Nat Rev Cancer 2002;2:38-47
14. Ihle JN. Cytokine receptor signaling. Nature 1995;377:591-4
15. Joung YH, Park JH, Park TK, Lee CS, Kim OH, Ye SK, Yang UM, Lee KJ, Yang YM. Hypoxia activates signal transducers and activators of transcription 5 (STAT5) and increases its binding activity to the GAS element in mammary epithelial cells. Exp Mol Med 2003;35:350-7
16. Kabotyanski EB and Rosen JM. Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b. J Biol Chem 2003;278:17218-27
17. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 1999;274:22484-92
18. Kim DM, Yang KM, Yang BS. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A. Exp Mol Med 2003;35:421-30
19. Lee MY, Joung YH, Lim EJ, Park JH, Ye SK, Park TK, Zhang Z, Park DK, Lee KJ, Yang YM. Phosphorylation and activation of STAT proteins by hypoxia in breast cancer cells. Breast 2005;in press (E-pub)
20. Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G., Haines GK 3rd, Webster M, Muller WJ, Brugge JS, Davies RJ, Pestell RG. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 1999;274:7341-50
21. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK 3rd, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000; 20:672-83
22. Leonard WJ and O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322
23. Liu JJ, Chao JR, Jiang MC, Ng SY, Yen JJ, Yang-Yen HF. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol 1995;15:3654-63
24. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11:179-86
25. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Restell RG., Kanakura Y. Transcriptioal regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 1999;18:1367-77
26. Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 1994;91:8022-6
27. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109:8121-31
28. Park JH, Lee HY, Roh SC, Kim HY, Yang YM. Screening of Differentially Expressed Genes by Desferrioxamine or Ferric Ammonium Citrate Treatment in HepG2 Cells. J Biochem Mol Biol 2000;33:396-401
29. Park JH, Park TK, Kim HY, Yang YM. The IGFBP-1 mRNA Expression in HepG2 Cells is Affected by Inhibition of Heme Biosynthesis. J Biochem Mol Biol 2001a;34:385-9
30. Park SH, Yamashita H, Rui H, Waxman DJ. Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: Impact on STAT5 transcriptional activity. Mol Endocrinol 2001b;15:2157-71
31. Pellegrini S and Dusanter-Fourt I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur J Biochem 1997;248:615-33
32. Pircher TJ, Petersen H, Gustafsson JA, Haldosen LA. Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. Mol Endocrinol 1999;13:555-65
33. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G. Austrian Breast and Colorectal Cancer Study Group. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7
34. Schroeder MD, Symowicz J, Schuler LA. PRL modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 2002;16:45-57
35. Simonart T, Degraef C, Andrei G, Mosselmans R, Hermans P. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol 2000;115:893-900
36. Simon AR, Takahashi S, Severgnini M, Fanburg BL, Cochran BH. Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002;282:L1296-L304
37. Storz P, Doppler H, Pfizenmaier K, Muller G. Insulin selectively activates STAT5b, but not STAT5a, via a JAK2-independent signalling pathway in Kym-1 rhabdomyosarcoma cells. FEBS Lett 1999;464:159-63
38. Tazuke SI, Mazure NM, Sugawara J, Carland G, Faessen GH, Suen LF, Irwin JC, Powell DR, Giaccia AJ, Giudice LC. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci USA 1998;95:10188-93
39. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 1997;94:7239-44
40. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71
41. Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon JM, Hennighausen L, Kirken RA, Rui H. Role of serine phosphorylation of Stat5a in prolactin-stimulated β-casein gene expression. Mol Cell Endocrinol 2001;183:151-63
42. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21